From Concept to Clinic: How T-VEC Validated Intratumoral Immunotherapy

The 2015 FDA and EMA approval of talimogene laherparepvec (T-VEC) for unresectable advanced melanoma was the defining regulatory event that transformed intratumoral (IT) immunotherapy from a promising hypothesis into a proven therapeutic modality. T-VEC — a recombinant HSV-1 encoding GM-CSF — demonstrated a durable response rate of 16.3% versus 2.1% for subcutaneous GM-CSF in its Phase 3 randomised trial, establishing IT intralesional injection as the approved delivery route and setting the benchmark against which all subsequent platforms are evaluated.

T-VEC’s mechanism is instructive for understanding the entire intratumoral pipeline. The virus selectively replicates in tumour cells that harbour defective interferon (IFN) signalling — a vulnerability shared across transformed cells — while the encoded GM-CSF recruits and matures dendritic cells at the tumour site, converting local oncolysis into systemic adaptive immunity. This dual action — direct cytotoxicity plus immune priming — is the mechanistic template that every subsequent platform attempts to replicate, extend, or improve upon.

Next-generation HSV engineering has moved beyond GM-CSF delivery. One approach documented in the pipeline involves retargeting HSV-1 to deliver adenosine deaminase for tumour adenosine clearance, directly addressing CD73/CD39-mediated immunosuppression — a signal that HSV payload engineering is evolving toward next-generation immunosuppression reversal strategies, not just cytokine delivery.

Viral Platform Diversity: Adenoviruses, NDV, and Beyond

Adenoviruses constitute the most represented viral backbone in the intratumoral pipeline, with diverse engineering strategies for tumour selectivity, payload delivery, and combinatorial activity documented across academic and commercial research. The breadth of adenoviral platform designs reflects the backbone’s tractability for genetic modification and its well-characterised biology in human cells.

Key adenoviral engineering strategies include E1A-deletion (D24) variants that restrict replication to Rb-pathway-defective tumour cells, tumour-selective promoter control using survivin, hTERT, Cox-2, and VEGF promoters, and fibre modifications (RGD insertion, Ad5/3 chimera) that expand tropism to CAR-low tumour cells. The TILT-123 platform — Ad5/3-E2F-d24 encoding TNF-α and IL-2 — was specifically highlighted as enabling anti-PD-L1 responses in urological tumour histocultures. Enadenotucirev (EnAd), a chimeric Ad11p/Ad3 platform from PsiOxus Therapeutics, enables intravenous delivery with tumour-selective replication and modular transgene cassette insertion for IT expression — a notable step toward systemic dosing with local immunostimulation.

Newcastle Disease Virus (NDV) — an avian paramyxovirus — is one of the most frequently described non-herpes, non-adeno platforms. Its natural tumour selectivity stems from defective IFN signalling in tumour cells, Rac1 GTPase targeting in RAS-transformed cells, and apoptosis induction via NP-mediated autophagy. Engineering approaches include NDV expressing IL-2, chimeric tumour-associated antibodies (such as anti-CD147 cHAb18 in hepatocellular carcinoma models), and checkpoint inhibitors. Notably, NDV induces PD-L1 upregulation even in lysis-resistant tumour cells, establishing a mechanistic rationale for OV plus checkpoint inhibitor combinations. Comparative data from Erasmus Medical Center shows that intratumoral NDV administration can be more effective than intravenous delivery in certain pancreatic adenocarcinoma xenograft models.

Vaccinia-based platforms — including JX-594 (pexastimogene devacirepvec) — have been evaluated via both IT and intravenous routes. A novel oncolytic vaccinia virus (NOV) with VGF/TK gene deletions and TRAIL/Ang1 insertion demonstrated pan-cancer selectivity across colon, liver, pancreas, melanoma, and other tumour types in preclinical work from Pusan National University. The TRAIL payload induces early apoptosis within 24 hours across multiple tumour cell lines. According to the FDA, the regulatory pathway for oncolytic biologics continues to evolve as the field matures.

STING Agonists and TLR Pathways as Non-Viral IT Agents

Intratumoral delivery of Toll-like receptor (TLR) agonists and STING pathway activators represents a distinct, non-viral local immunostimulation modality — one that exploits the same innate immune circuitry as oncolytic viruses but through small-molecule or oligonucleotide pharmacology rather than replicating agents.

The TLR agonist landscape documented in the pipeline spans the full range of endosomal receptors. CpG oligodeoxynucleotides (TLR9 agonists) delivered intratumorally in combination with radiation therapy generated in situ tumour vaccination in murine models, elevating IFN-γ and reducing lung metastases. The TLR7/8 agonist 3M-052 was described as most effective in dermatological cancers following IT administration. Poly(I:C) (TLR3) combined with CD40L nanoparticles showed synergy with CpG in a B16F10 melanoma model. A 2022 review from the University of Navarra documented that IT and draining lymph node injection of TLR3, TLR7, TLR8, and TLR9 agonists achieves abscopal effects and immunological memory in solid tumour models — a critical validation of the systemic reach of local immunostimulation.

The STING-TBK1-IRF3 axis occupies a mechanistic bridge between oncolytic virus biology and innate immune pharmacology. Research from Zhejiang University demonstrated that oncolytic adenovirus infection — particularly via cytosolic DNA sensing in dendritic cells — activates the STING pathway, with Ad-IL15-induced STING signalling driving vascular normalisation and tertiary lymphoid structure (TLS) formation in murine tumour models. TLS formation is associated with improved antitumour immunity and better responses to checkpoint inhibitors, making STING activation a high-value downstream endpoint for IT therapies. As documented by the NIH, STING pathway research has accelerated substantially as a target class for cancer immunotherapy.

“Intratumoral and draining lymph node injection of TLR3, TLR7, TLR8, and TLR9 agonists achieves abscopal effects and immunological memory in solid tumour models — validating the systemic reach of purely local immunostimulation.”

Non-viral IT agents also include nanoparticle-delivered CD40L DNA plasmids for melanoma, combining costimulatory CD40 pathway activation with TLR agonists. The 2019 IT immunotherapy landscape review from The Angeles Clinic and Research Institute also references PV-10 as part of the broader non-oncolytic IT agent class. Research published via WIPO-tracked patent filings shows that combination approaches pairing TLR agonists with oncolytic agents are increasingly protected through commercial IP strategies.

Transgene Payloads and Molecular Targets Driving Pipeline Differentiation

The choice of transgene payload is increasingly the primary differentiator among oncolytic virus platforms sharing the same viral backbone. GM-CSF remains the most frequently encoded transgene in the pipeline — present in T-VEC, JX-963, and multiple adenoviral constructs — functioning by recruiting and maturing dendritic cells at the tumour site to convert local oncolysis into systemic adaptive immunity.

The TILT-123 platform (Ad5/3-E2F-d24-hTNFa-IRES-hIL2) from TILT Biotherapeutics and the University of Helsinki encodes both TNF-α and IL-2, promoting lymphocyte trafficking via CXCL10 upregulation, IFN-γ and granzyme B production, and enabling anti-PD-L1 activity in urological tumour histocultures in vitro and syngeneic in vivo models. Bilateral tumour models demonstrated abscopal control of non-injected tumours — a critical proof-of-concept for systemic reach via IT injection.

IL-15 (Ad-IL15) activates the STING pathway and promotes DC, T cell, and NK cell infiltration in murine tumour models, as shown by Zhejiang University. IL-12 — carried by Ad5-ZD55-hCCL5-hIL12 — facilitates CAR-T therapy targeting carbonic anhydrase 9 (CA9) for renal cell carcinoma via STAT4 phosphorylation and CCL5-mediated T cell recruitment. TRAIL (TNF-related apoptosis-inducing ligand), incorporated into oncolytic vaccinia (NOV) in place of VGF, induces early apoptosis within 24 hours across multiple tumour cell lines.

Beyond cytokines, the pipeline documents anti-PD-L1 scFv delivery via adenovirus (Ad5Δ24-anti-PD-L1-scFv), which showed enhanced tumour cell death in B16.OVA melanoma co-culture models — effectively combining oncolytic activity with local checkpoint blockade in a single construct. The p53 restoration strategy — using oncolytic adenoviruses that silence SYVN1 (synoviolin), a p53 inhibitor — adds another layer of tumour suppressor pathway targeting to the oncolytic mechanism. Research standards from ISO and regulatory guidance from bodies including the EMA continue to shape how transgene-armed oncolytic biologics are characterised and evaluated for clinical entry.

Combination Strategies: Checkpoint Inhibitors, CAR-T, and Adoptive Cell Therapy

The dominant emerging signal across 2020–2023 pipeline records is convergence on combination strategies that pair intratumoral agents with systemic immunotherapies — most prominently immune checkpoint inhibitors, adoptive cell therapies, and CAR-T platforms. The mechanistic rationale is consistent across combinations: IT injection converts immunologically “cold” tumours into inflamed (“hot”) microenvironments permissive to systemic therapy activity.

OV + Immune Checkpoint Inhibitors

The OV plus checkpoint inhibitor combination is the most frequently documented emerging strategy. OV infection upregulates PD-L1 on tumour cells — a barrier to OV monotherapy efficacy — while simultaneously generating immunogenic tumour antigen release. TILT-123 combined with anti-PD-1, and NDV combined with CTLA-4 blockade, are specifically described in bilateral tumour models showing abscopal control of non-injected tumours. Coxsackievirus A21 (CAVATAK) in combination with checkpoint blockade significantly reduced tumour growth and improved survival in an immune-competent mouse melanoma model in Phase II-referenced data from Huntsman Cancer Institute.

OV + Adoptive Cell Therapy (TIL)

Research from the University of Pittsburgh and the University of Helsinki documents OV-primed tumour-infiltrating lymphocyte (TIL) extraction and reinfusion strategies. IT poxvirus injection in low-immunogenicity MC38 tumours elicited tumour-specific TIL populations suitable for adoptive cell therapy. Most strikingly, oncolytic adenoviruses encoding TNF-α and IL-2 cured 100% of Syrian hamsters in combination with TIL transfer — a result that has accelerated interest in the OV-as-primer concept for cell therapy programmes.

OV + CAR-T Therapy

A 2023 study from Xuzhou Medical University describes Ad5-ZD55-hCCL5-hIL12 priming tumour lesions via CCL5-mediated T cell recruitment and IL-12 costimulation to enhance CA9-targeting CAR-T activity against renal cell carcinoma. The OV-as-primer concept for cell therapy is gaining traction as a strategy to address the CAR-T trafficking and persistence limitations in solid tumours — a challenge well-documented in the broader PatSnap innovation intelligence literature on cell therapy.

“IT injection of oncolytic virus converts immunologically ‘cold’ tumours into inflamed ‘hot’ microenvironments — the prerequisite for checkpoint inhibitor and adoptive cell therapy activity in solid tumours.”

Patent activity reinforces these combination directions. Oncolytics Biotech filed two patents (Israel jurisdiction, both now inactive) claiming methods of enhancing oncolytic reovirus efficacy via co-administration of immunostimulants including CpG oligodeoxynucleotides and dendritic cell-delivered viral antigens. DNAtrix, Inc. holds a pending Singapore-jurisdiction patent covering biomarkers and combination therapies with oncolytic adenoviruses and immunomodulators in glioma contexts. These filings signal that the OV plus immunostimulant combination space attracted early commercial IP interest, with more recent activity focused on biomarker-stratified patient selection — a signal of pipeline maturation. Explore the full assignee and combination patent landscape using PatSnap’s innovation intelligence platform.